Phaxiam Therapeutics announces the inclusion of the first patient in its Phase 1 clinical trial in infective endocarditis caused by Staphylococcus aureus (S. aureus), involving 12 patients in five French clinical centers.

The study, whose first results are expected in the third quarter of 2024, will evaluate intravenous administration of phages, 'particularly well-suited to address indications with very high medical stakes'.

The main cause of infective endocarditis, the S. aureus bacterium is responsible for around 30% of cases of this heart disease, which can lead to heart failure, heart valve lesions and strokes.

Copyright (c) 2024 All rights reserved.